- Neximmune press release ( NASDAQ: NEXI ): Q2 GAAP EPS of -$0.69 misses by $0.01 .
- Shares +3.2% AH.
- Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug ( IND ) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related cancers
- Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22
- Clinical updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 4Q22
- Company is prioritizing resources to support Company’s lead product candidates, NEXI-001 and NEXI-003
For further details see:
Neximmune GAAP EPS of -$0.69 misses by $0.01